# CJC-1295 References: The Cited Research Literature

> CJC-1295 references — the full cited literature behind this review, with DOIs, PMIDs and PubMed links: Teichman 2006, Jette 2005, Ionescu 2006, the detection methods, and the 2025 GHRH-analog review.

Every quantitative claim on this site maps to a numbered entry below. PMIDs and DOIs are provided so each source can be resolved directly.

## How to Read These Citations

Every inline [N] marker across this site resolves to the matching number below. The core CJC-1295 pharmacokinetic record rests on a small set of primary studies — Jette 2005, Teichman 2006 and Ionescu/Frohman 2006 — with the detection literature and the 2025 GHRH-analog review providing the analytical and contemporary context. Where a source is paywalled, the PMID or DOI still resolves to its abstract and metadata. The full citation list is reproduced below.

## References

[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[3] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[4] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[6] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233
[7] An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormone analogs. J Pharm Biomed Anal. 2022. https://pubmed.ncbi.nlm.nih.gov/35298973/
[8] Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. https://pubmed.ncbi.nlm.nih.gov/34665524/
[9] Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-MS. Anal Bioanal Chem. 2016. https://pubmed.ncbi.nlm.nih.gov/26879649/
[10] Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea kinetics. Growth Horm IGF Res. 2009. https://pubmed.ncbi.nlm.nih.gov/19231263/
[11] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[12] CJC-1295 development, pharmacokinetics, and regulatory status: ConjuChem Phase 2 program (NCT00267527, discontinued); 2024 FDA Pharmacy Compounding Advisory Committee review (reviewed, not recommended for the 503A bulks list); WADA Prohibited List Section S2; and the GH/IGF-1-axis safety literature (fluid retention, insulin sensitivity, IGF-1/cancer epidemiology). Composite of primary regulatory and clinical-trial records. https://clinicaltrials.gov/study/NCT00267527
[13] Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control. J Mass Spectrom. 2024. https://pubmed.ncbi.nlm.nih.gov/38197510/
[14] Analysis of growth hormone releasing hormone and its analogs in urine using nano-LC-MS. J Pharm Biomed Anal. 2025. https://pubmed.ncbi.nlm.nih.gov/41138283/

---

A scroll-told review of the CJC-1295 literature, read top to bottom in the order the evidence accrued — the DAC and no-DAC tracks kept apart, every figure logged to its study and the human gaps left visibly open; no clinic behind the rail and nothing here dispensed or for sale.